Cubist Systematic Strategies’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Cubist Systematic Strategies’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-59,063	Closed	-$593K	–	4434
2023 Q4	$593K	Buy	59,063 +57,656	+4,098%	+$262K	﹤0.01%	2430
2023 Q3	$4.05K	Sell	1,407 -1,671	-54%	-$6.11K	﹤0.01%	3178
2023 Q2	$11.7K	Sell	3,078 -9,333	-75%	-$26.1K	﹤0.01%	3246
2023 Q1	$23.1K	Buy	+12,411	New	+$25.9K	﹤0.01%	3660

Cubist Systematic Strategies's GRCL Position: Q1 2024 in Review

Cubist Systematic Strategies sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 59,063 shares — an estimated $593K sold.

Cubist Systematic Strategies first reported a position in GRCL in Q1 2023 and held it in 4 quarters. The position peaked at $593K in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Cubist Systematic Strategies reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Cubist Systematic Strategies sold 59,063 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $593K.
Cubist Systematic Strategies first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2023 and held it in 4 quarters.
Cubist Systematic Strategies's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $593K in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Cubist Systematic Strategies's 13F filing for Q1 2024, filed 15 May 2024.